Previous 10 | Next 10 |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 4, 2024) - Faruqi & Faruqi, LLP, a leading national secur...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders i...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 2, 2024) - Faruqi & Faruqi, LLP, a leading national secur...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 28, 2024) - Faruqi & Faruqi, LLP, a leading national se...
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)? Did you purchase your shares between February 1, 2022 and January 1, 2024, inclusive? Did you lose money in your in...
Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ:AVXL)? Did you purchase your shares between February 1, 2022 and January 1, 2024, inclusive? Did you lose money in your investment in Anavex Life Sciences Corporation? Do you want to discuss your rights? ...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 4, 2024) - Faruqi & Faruqi, LLP, a leading national sec...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 2, 2024) - Faruqi & Faruqi, LLP, a leading national sec...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behal...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares. Investors, who purchased Anavex Life Sciences Corp. (NASDAQ: AVXL) shares prior to Februa...